Form 4: Syndax Pharmaceuticals Director Rizo Acquires 25,000 Shares of Common Stock

Director Aleksandra Rizo acquired 25,000 shares of Syndax Pharmaceuticals common stock on February 5, 2025, through an award of restricted stock units.

Summary

• Aleksandra Rizo, a director of Syndax Pharmaceuticals Inc., acquired 25,000 shares of common stock on February 5, 2025.
• The acquisition was in the form of restricted stock units (RSUs).
• The RSUs vest one year from the date of grant.
• The shares underlying the RSUs will not be delivered, transferred, or sold until the earlier of separation from service, death, disability, or change in control.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, but the restrictions on the stock units temper the immediate impact.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future.

Risks

• The restricted nature of the stock units means the director cannot immediately sell the shares, which could limit the immediate impact on the stock price.

Future Outlook

The vesting of the restricted stock units is contingent upon continued service or certain events like death, disability, or change in control, suggesting a long-term commitment from the director.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock. This particular filing indicates a director's acquisition of shares, which is generally viewed positively by investors.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates